I did a little more digging and found that they are presenting incomplete data from a third line trial that got cut short due to enrollment issues: This tells me that the most effective strategy is to have a clear timeline of opening and closing a position since anyone holding indefinitely will get tired of seeing the sell orders.
Michael Demurjian and Steve Hoffman have over 20 million shares and they have flooded the insider filings with their constant selling. The only detracting factor is that two insiders are using the stock as their personal piggy bank. I've seen biotechs trade under cash value when there's a failure, so I wouldn't think there's no risk at these levels, but the risk appears relatively low. They raised $100 million last year and stashed away about $80 million into "a portfolio of highly liquid investments and marketable securities. The primary objectives of the Company’s policy are to preserve capital and diversify risk, while maintaining sufficient liquidity to meet cash flow requirements."Īt about $110M, their market cap is pretty close to the cash value. Bigger than the cash on hand would indicate. Syros Pharmaceuticals is set to acquire a New Jersey biotech firm called Tyme Technologies Inc., extending its cash runway into 2025 at a time when biotech stocks are being hammered.Tyme is sitting on a big cash reserve. Syros to acquire New Jersey biotech Tyme Technologies Mergers and acquisitions are starting to ramp up in Massachusetts' life sciences sector, but analysts believe the biggest buys are still yet to come. M&A activity picks up among life sciences firms (“Syros”) and “FOR” all other matters to be voted upon at the Company’s upcoming Special Meeting of Stockholders (the (“ISS”) have recommended that Tyme stockholders vote “FOR” the previously announced merger of Tyme and Syros Pharmaceuticals, Inc. (“Glass Lewis”) and Institutional Shareholder Services Inc. (NASDAQ:TYME) (“Tyme” or the “Company”), today announced that independent proxy advisory firms Glass, Lewis & Co. 07, 2022 (GLOBE NEWSWIRE) - Tyme Technologies, Inc. Announces Proxy Advisory Firms Glass Lewis and ISS Recommend Stockholders Vote “FOR” Proposed Merger of Syros and TymeīEDMINSTER, N.J., Sept. (NASDAQ:TYME) today announced the results of the special meetings of the stockholders of Syros and TYME, respectively, each held on September 15, 20 (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, and Tyme Technologies, Inc. 15, 2022 (GLOBE NEWSWIRE) - Syros Pharmaceuticals, Inc. Combined Company to Trade on Nasdaq Under Ticker “SYRS” - Syros Announces 1-for-10 Reverse Stock Split of Common Stock - CAMBRIDGE, Mass. Syros and Tyme Technologies Announce Stockholder Approval of Merger William White on InvestorPlace | September 16, 2022 We're starting off the final trading day of the week with a look at the biggest pre-market stock movers for Friday and what's moving them! Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday Below are the latest news stories about TYME TECHNOLOGIES INC that investors may wish to consider to help them evaluate TYME as an investment opportunity.
0 kommentar(er)
